Core B consists of three separate but integrated sectionsdesigned to facilitate successful completion of the aims and studies performed in Projects I, II and III, and Core A. It is designed to provide cells, genetic material and molecular diagnostic information to aid in the design and construction of therapeutic gene delivery systems for JEB patients. The cell culture section will accession all EB skin and blood samples, bank genetic material, growth and freeze EB keratinocytes, fibroblasts, endothelial cells and immortalize keratinocytes and lymphocytes. It will provide other sections of Core B and the program projects with normal cells, immortalized cells and non-immortalized JEB cells for gene therapy. The molecular diagnostics section of Core B will provide detailed information about deficient or defective JEB candidate genes and gene products produced by patient skin cells both in situ and in vitro. It willfacilitate DNA mutation analysis of individual JEB pateints and families by narrowing the search for candidate gene mutations and interface with collaborators performing candidate gene polymorphism studies. The diagnostics section will provide ghe gene transfer section of Core B and all program projects with information needed to tailor design appropriate gene therapy vectors for individual JEB patients. The gene transfer and verification section of Core B will be responsible for the introduction of therapeutic genes into non-immortalized JEB keratinocytes, the testing of these engineered cells for any possible contamininants and the construction of monolayer keratinocyte autografts and organotypic dermal equivalents for JEB patient grafting. Core B will interface with Core A in three specific ways; 1) by accepting EB patient samples, 2) by providing diagnostion for clinicians and EB patients/families, and 3) by providing JEB keratinocyte autografts and tailor-disigned therapeutic gene delivery constructs for ex vivo gene therapy.

Project Start
1998-07-01
Project End
1999-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
2
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Vijayakumar, Soundarapandian; Dang, Suparna; Marinkovich, M Peter et al. (2014) Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD. Am J Physiol Renal Physiol 306:F640-54
Gao, Jing; DeRouen, Mindy C; Chen, Chih-Hsin et al. (2008) Laminin-511 is an epithelial message promoting dermal papilla development and function during early hair morphogenesis. Genes Dev 22:2111-24
Tran, Mark; Rousselle, Patricia; Nokelainen, Pasi et al. (2008) Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res 68:2885-94
Waterman, Elizabeth A; Sakai, Noriyasu; Nguyen, Ngon T et al. (2007) A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res 67:4264-70
Pullar, Christine E; Baier, Brian S; Kariya, Yoshinobu et al. (2006) beta4 integrin and epidermal growth factor coordinately regulate electric field-mediated directional migration via Rac1. Mol Biol Cell 17:4925-35
Li, Jie; Zhou, Lisa; Tran, Hoang T et al. (2006) Overexpression of laminin-8 in human dermal microvascular endothelial cells promotes angiogenesis-related functions. J Invest Dermatol 126:432-40
Gonzalez-Quevedo, Rosa; Shoffer, Marina; Horng, Lily et al. (2005) Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. J Cell Biol 168:453-63
Yant, Stephen R; Wu, Xiaolin; Huang, Yong et al. (2005) High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25:2085-94
Ortiz-Urda, Susana; Garcia, John; Green, Cheryl L et al. (2005) Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science 307:1773-6
Arbiser, Jack L; Fan, Chun-Yang; Su, Xiaobo et al. (2004) Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 123:788-90

Showing the most recent 10 out of 58 publications